Why I think it might finally be time to buy FTSE 100 dividend stock GlaxoSmithKline

Shares in drugmaker GlaxoSmithKline plc (LON:GSK) responded well to an update on trading. Paul Summers likes the stock a lot more than he used to.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

In keeping with its tradition of releasing results in time to catch US markets opening, pharmaceuticals giant GlaxoSmithKline (LSE: GSK) revealed its latest trading update at noon today.

Given the (initial) increase in the share price this afternoon, it seems many UK investors are more than satisfied with what the Brentford-based business had to say.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Sales up

Group sales over the third quarter of its financial year hit £8.1bn — a rise of 6% at constant exchange rates (CER).  This brings the drugmaker’s total turnover for the first nine months to £22.6bn — 4% higher once currency fluctuations are taken into account. At £4.2bn, the majority of this came from its Pharmaceuticals business. Sales at Consumer Healthcare and Vaccines — Glaxo’s two other businesses — both rose to £1.9bn with the latter registering growth of 17%. 

Total New Respiratory product sales soared 40% to £645m over the reporting period with the company’s Relvar Ellipta inhalers and add-on treatment Nucala bringing in £500m and £145m respectively. Elsewhere, sales of HIV drugs Tivicay and Triumeq climbed 13% to £1.1bn. 

Taking all this into account, adjusted operating profit grew 6% over the period to £2.52bn and 7% over the first nine months to £6.55bn. Adjusted earnings per share came in at a better-than-expected 35.5p (+14% CER)

Positively for those already holding its stock, Glaxo announced today that it would be revising its guidance for the full year “towards the upper end of previous expectations“. Thanks to bumper sales of Shingrix (likely to be £700m-£750m in the current financial year after bringing in £286m over Q3) and improved cost control, adjusted earnings per share growth of between 8%-10% at constant exchange rates is now predicted.  Interestingly, this is regardless of whether a generic competitor to its blockbuster Advair — used to prevent asthma attacks by relaxing muscles in the airways — is introduced in the US. 

A screaming buy?

GlaxoSmithKline’s stock was trading a little under 14 times earnings before trading commenced this morning. Compared to other companies in its industry, that’s pretty cheap. It’s certainly better valued than FTSE 100 peer Astrazeneca, which requires investors to fork out 22 times earnings to acquire its stock at the current time, although the latter does arguably have better growth prospects going forward.

The real draw for many investors, however, remains Glaxo’s bumper yield. As expected, the company revealed a 19p per share dividend for the quarter. A total payout of 80p for the financial year was also reiterated — something that hasn’t changed since 2014.

Based on its today’s share price, that leaves Glaxo yielding 5.2%. While I don’t expect significant hikes going forward, the extent to which these cash returns are likely to be covered by profits is beginning to look far healthier. I fully confess to being sceptical over the company’s ability to avoid taking a knife to its dividend over the last couple of years but, at £2.38bn, the 42% improvement in free cash flow over the year to date makes Glaxo’s income credentials a lot stronger. 

It might not be a screaming buy, but today’s numbers have led me to revise my view on the company. At a time when many investors are clamouring for security as a response to ongoing trade tensions between the US and China, to interest rate rises and our forthcoming EU departure, I think purchasing slices of non-cyclical, globally diversified businesses like Glaxo could be a sound move. 

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Preparing a budget during a pandemic
Investing Articles

2 high-potential FTSE 250 stocks to buy and hold for 5 years!

The FTSE 250 is a good place to search for the next big British stocks. So, here are two companies…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Could my Stocks and Shares ISA generate £30,000 a year?

Over 2m UK citizens make some use of a Stocks and Shares ISA every year. Our writer considers if it’s…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

4 dividend stocks that can help me fight inflation!

I'm looking at dividend stocks to help my portfolio grow and overcome the impact of high inflation. Here are the…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

2 bargain UK shares trading at less than book value

Book value is a great way to value a stock. These UK shares are trading at a price-to-book ratio of…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

A FTSE AIM stock I’d add to my Stocks & Shares ISA in July

Henry Adefope highlights a FTSE AIM stock he believes could generate significant upside for his portfolio if he buys this…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’m following Warren Buffett and buying cheap dividend shares to build my wealth

I think this cheap dividend stock exhibits similar qualities to the companies Warren Buffett has in his investment portfolio.

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

2 cheap FTSE 100 shares I’m buying during the dip!

Andrew Woods explains that low P/E ratios and profitable businesses attract him to these two FTSE 100 shares.

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Down 45% in a year, is now the time to buy Scottish Mortgage shares?

Jon Smith explains why Scottish Mortgage shares appear to him to be good value given their post-pandemic fall.

Read more »